北京若生智能科技有限公司
Drug Database
AL

alendronate (Binosto / Steovess / EX101)

✓ Approved

Ahn-Gook Pharmaceutical · 小分子 · 小分子

什么是 alendronate？

alendronate 是一种小分子，由Ahn-Gook Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Binosto, Steovess, EX101
公司Ahn-Gook Pharmaceutical
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Ahn-Gook Pharmaceutical

治疗适应症

alendronate 针对 3 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved
Congenital, familial and genetic disordersHypertrophic cardiomyopathyPhase III
Musculoskeletal and connective tissue disordersOsteoarthritisPhase II

相关研究文献

PubMedJournal of molecular histology2026-09-10

Naringin attenuates orchidectomy-induced bone loss in male rats: evidence from bone remodeling and telomere-related indices.

Zhong Yelin Y, Wu Guoying G, Xiong Shishuo S, Zhang Yukai Y et al.

Androgen deficiency contributes to secondary osteoporosis in men, yet the effects of naringin in androgen-deficient male bone loss remain unclear. We evaluated whether naringin attenuates orchidectomy (ORX)-induced bone loss in male Sprague-Dawley rats and whether this response is accompanied by changes in bone turnover, the OPG/RANKL axis, TERT expression, and relative telomere length. Forty rats were assigned to Sham, ORX, ORX + Naringin, and ORX + Alendronate (ALN) groups. Treatments were administered by oral gavage for 8 weeks. ORX impaired L4 trabecular microarchitecture, shifted serum bone turnover markers toward resorption, reduced the OPG/RANKL ratio, lowered TERT expression, and shortened relative telomere length. Naringin improved BV/TV, Tb.N, Tb.Th, and Tb.Sp; increased OCN and PINP; reduced CTX-I and TRACP-5b; and partially restored the OPG/RANKL balance compared with untreated ORX rats. Naringin was also associated with higher TERT expression and longer relative telomere length, whereas alendronate produced comparable structural and turnover responses but weaker telomere-related changes. These findings suggest that naringin attenuates ORX-induced bone loss in male rats, with coordinated changes in skeletal remodeling and telomere-related indices.

PMID 42717104
阅读全文 →
PubMedMikrochimica acta2026-09-09

Smartphone-based visual quantitation of glyphosate in liquid media using effervescent colorimetric tablets encompassing Ru-doped MOF with augmented enzyme-like activity.

Pan Yong Y, Hou Xiaofeng X, Li Chengyu C, Wang Xuedong X et al.

Although glyphosate is widely applied as a non-selective herbicide in agricultural production, its rapid and on-site monitoring remains challenging. Building upon magnetic effervescent tablets (METs) previously developed by our group, we designed novel METs-based colorimetric tablets (MCTs) using Ru-doped Fe-MOF (Ru40/Fe-MOF) with significantly enhanced peroxidase-mimetic activity. MCTs were integrated with smartphone-based digital-image chromogenesis (SDC) for visual quantitation of glyhosate in surface waters and liquid drinks. Ru-doping not only increased the specific surface area and regulated MOFs' morphology, but also prominently improved the underlying catalytic activity. Upon the addition of H2O2, Ru40/Fe-MOF catalyzed the chromogenic substrate ABTS to form a green oxidized product oxABTS, yielding a bright green solution. However, glyphosate could inhibit the aforementioned catalytic activity through coordination and/or H-bonding interactions with the surface groups of Ru40/Fe-MOF (-COOH, -NH2, Fe-OH, and Ru sites). MCTs enabled rapid auto-dispersion and chromogenic development upon contact with water, thereby eliminating the need for external stirring, shaking or heating. Under optimized conditions, the MCTs-SDC platform exhibited an excellent linearity for glyphosate with a detection limit of 0.006 µg/mL by UV-vis measurement and 0.03 µg/mL by grayscale analysis via a self-developed "Thing Identify" APP. In the lake water and liquid drink samples, the fortified recoveries (94.5-112.2%) by the MCTs-SDC were comparable to those by conventional water-bath-assisted colorimetry and HPLC-DAD analysis. Overall, this work provides a user-friendly, rapid, and on-site smartphone-based visual quantitation scheme for glyphosate in complex liquid media.

PMID 42711578
阅读全文 →
PubMedIranian journal of pharmaceutical research : IJPR2026-09-09

Comparison of Naringenin and Alendronate in the Attenuation of Ovariectomy-Induced Osteoporosis by Modulating Autophagy, Apoptosis, and Oxidative Stress in Rats.

Gao Hongwei H, Ma Pengcheng P, Chen Huizhi H, Zhang Zhengkai Z et al.

Estrogen deficiency after menopause is a major driver of osteoporosis and has been increasingly linked to dysregulated cellular stress responses, including autophagy and apoptosis, that affect bone remodeling and microarchitecture. This study aimed to evaluate the therapeutic effects of naringenin (NA) and alendronate (AL) on ovariectomy (OVX)-induced osteoporosis in rats, with emphasis on autophagy- and apoptosis-related molecular signatures. Female Sprague-Dawley rats were assigned to sham-operated (SH), OVX, OVX+NA (50 mg/kg/day), or OVX+AL (5 µg/kg/day) groups (n = 10/group) and were treated by oral gavage for 10 weeks. Bone health markers, including bone cell numbers and trabecular weight and volume, were assessed using stereology. Serum estradiol and osteocalcin levels were assayed by enzyme-linked immunosorbent assay. Oxidative markers, including catalase (CAT) and glutathione reductase (GR) activities, were measured using spectrophotometric assays. Femoral mRNA expression of microtubule-associated protein 1 light chain 3 (LC3), beclin 1 (BECN1), autophagy-related 5 (ATG5), caspase 9 (CASP9), and B-cell lymphoma 2 (BCL2) was quantified by reverse transcription quantitative polymerase chain reaction. Ovariectomy reduced estradiol levels compared with SH, and estradiol was not restored by NA or AL. Both treatments mitigated OVX-associated changes in osteocalcin and improved femoral stereological/histomorphometric outcomes, with AL exerting a greater effect across multiple structural and molecular outcomes. NA, but not AL, significantly increased CAT and GR activities relative to OVX. Ovariectomy increased CASP9 and autophagy markers and decreased BCL2; both treatments shifted these transcripts toward SH values, with a stronger effect for AL. Naringenin and AL mitigated OVX-associated osteoporotic changes without restoring systemic estradiol levels, and these effects were accompanied by shifts in apoptosis- and autophagy-related gene expression. These findings suggest that the beneficial effects of AL and NA may be associated with the modulation of oxidative stress and apoptosis- and autophagy-related mechanisms.

PMID 42713413
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-09-08

Tumor-Adhesive Ru/Ca-Tannic Acid Network Enables Phosphate-Independent Calcification and Photothermal-Synergistic Therapy for Osteolytic Bone Metastasis.

Li Xinyi X, Li Jinfeng J, Zeng Yaoxun Y, Dong Jiapeng J et al.

Osteolytic bone metastasis remains difficult to treat because effective tumor eradication and bone regeneration must be achieved simultaneously. Current calcification-based strategies are constrained by their reliance on exogenous phosphate, and poor integration with controllable therapeutic modalities. Herein, we report a tumor adhesive metal-phenolic network nanoplatform that enables phosphate-independent membrane biomineralization combined with photothermal amplification. The Ru/Ca-TA-ALN network, assembled from ruthenium ions (Ru3+), calcium ions (Ca2+), tannic acid (TA), and alendronate (ALN), co-integrates Ca2+ and phosphate-bearing moieties within a single coordination framework, allowing autonomous mineral deposition upon adhesion to tumor cell membranes. This membrane-confined calcified interface induced S-phase arrest, and impaired tumor viability. Under 1064 nm near-infrared (NIR) irradiation, Ru3+-mediated photothermal activation amplifies tumor cell apoptosis. Beyond tumor inhibition, the calcified nano-bio interface promoted osteogenic differentiation while suppressing osteoclastogenesis, shifting the bone microenvironment toward regeneration. In a murine breast cancer bone metastasis model, calcification-photothermal synergy significantly reduced tumor burden, mitigated bone destruction, and prolonged survival, while maintaining favorable biocompatibility. By transforming biomineralization into a controllable interfacial therapeutic modality, this work establishes a strategy that couples tumor suppression with bone reconstruction for metastatic bone disease.

PMID 42708173
阅读全文 →
PubMedAnnals of pediatric endocrinology & metabolism2026-09-07

Bisphosphonate therapy for thalassemia-related bone disorders in children and young adults: a systematic review.

Mangkuliguna Ghea G, Handisurya I Wayan Andrew IWA, Adrianto Nicholas N

Skeletal complications represent a major morbidity in transfusion-dependent thalassemia (TDT), particularly among children and young adults. Osteopenia and osteoporosis arise from marrow expansion, iron overload, endocrine dysfunction, and vitamin D deficiency, leading to impaired bone mass accrual. Although bisphosphonates are widely used in osteoporosis, their role in thalassemia has not been systematically appraised. This review aims to evaluate the role of bisphosphonates in pediatric and young adult patients with TDT-related bone disorders. A systematic search of PubMed/MEDLINE, Scopus, Cochrane Library, ProQuest, and gray literature was conducted from inception to August 2025. Eligible studies included randomized, nonrandomized, and prospective observational trials evaluating bisphosphonates in patients ≤25 years with TDT-related osteopenia or osteoporosis. Primary outcomes were changes in lumbar spine and hip bone mineral density (BMD). Secondary outcomes included biochemical markers, bone pain, fracture incidence, and safety. The review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020 guidelines and was registered in PROSPERO (CRD420251138498). Eleven nonrandomized prospective studies involving over 300 participants were included. Six studies evaluated pamidronate, 3 zoledronate, and 2 alendronate. Pamidronate generally improved lumbar spine and hip BMD, with more consistent gains when combined with calcium/vitamin D. Zoledronate was associated with BMD improvement but required pediatric-adjusted dosing to avoid hypocalcemia. Alendronate improved BMD z-scores and reduced bone pain in adolescents. Across studies, bisphosphonates lowered bone turnover markers and were generally well tolerated. Bisphosphonates may improve bone density and alleviate pain in TDT-related bone disease. Larger randomized controlled trials are required to determine long-term efficacy, fracture outcomes, and optimal treatment regimens.

PMID 42705655
阅读全文 →
PubMedMedicine2026-09-06

Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis: A GRADE-assessed systematic review and meta-analysis.

Shah Asim A, Khan Suleman S, Rizvi Syeda Vilay Zehra SVZ, Farhan Kanza K et al.

Denosumab cessation causes rebound bone turnover, fast bone loss, and an elevated risk of vertebral fractures. Pooled data about the fracture prevention efficacy of potent bisphosphonates (BPs) as sequential therapy have been lacking to counteract this risk. This systematic review and meta-analysis was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed, Scopus, the Cochrane Library, and ClinicalTrials.gov were searched from the beginning through May 1, 2026. Included studies comprised adults with osteoporosis or low bone mass who discontinued denosumab and subsequently received potent BP therapy, defined as alendronate or zoledronic acid, compared with no subsequent antiresorptive therapy or a selective estrogen receptor modulator (SERM). Random-effects meta-analyses were performed using the Mantel-Haenszel method to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Prespecified subgroup analyses were conducted based on comparator type. The Grading of Recommendations Assessment, Development and Evaluation assessment method was applied to assess the certainty of the evidence. Six studies were included; 683 participants contributed to the primary incident vertebral fracture analysis. Potent BP therapy was linked to a considerable reduction in incident vertebral fractures (RR = 0.29; 95% CI: 0.14-0.59; 71% relative risk reduction), multiple vertebral fractures (RR = 0.08; 95% CI: 0.01-0.43; 92% relative risk reduction), and clinical vertebral fractures (RR = 0.18; 95% CI: 0.07-0.49; 82% relative risk reduction). The protective effect was driven mainly by comparisons with no subsequent therapy, while comparisons with SERM therapy were limited and not statistically significant. There was no statistically significant reduction in any fracture (RR = 0.35; 95% CI: 0.10-1.24) or non-vertebral fracture (RR = 0.43; 95% CI: 0.07-2.64). Overall certainty of evidence was low to very low, mainly due to the observational nature of most included studies and imprecision in several outcomes. Potent BP therapy was related to decreased vertebral fracture risk after denosumab termination, particularly when compared with no subsequent therapy. Evidence versus SERM comparators was limited and inconclusive. The results are in agreement with the present clinical guideline recommendations for sequential BP use after the discontinuation of denosumab, but further high-quality randomized trials are required to prove this.

PMID 42700089
阅读全文 →

注册免费账户还可查看另外 6945 篇文献

免费注册查看全部文献 →

了解更多alendronate